Pneumocystis jirovecii pneumonia as a complication of etoposide therapy

Maria Alejandra Mendoza, Sunil Iyer, Jose F. Camargo, Pasquale W. Benedetto

Research output: Contribution to journalArticlepeer-review


Two patients receiving oral etoposide therapy developed Pneumocystis jirovecii pneumonia during chemotherapy with significant lymphopenia without corticosteroid use. In this commentary we discuss cellular mechanisms by which etoposide induced CD4+ T lymphocyte dysfunction and reduced survival may lead to predisposition to P. jirovecii infection.

Original languageEnglish (US)
Article numbere242485
JournalBMJ case reports
Issue number6
StatePublished - Jun 10 2021


  • haematology (incl blood transfusion)
  • infections
  • malignant disease and immunosuppression
  • pneumonia (infectious disease)

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Pneumocystis jirovecii pneumonia as a complication of etoposide therapy'. Together they form a unique fingerprint.

Cite this